Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Nanoparticle-Assisted liquid biopsy based on Extracellular for Early Diagnosis of Glioblastoma

Descrizione del progetto

Biopsia liquida per la diagnosi del glioblastoma

Le vescicole extracellulari sono piccole particelle rilasciate da quasi tutti i tipi di cellule nello spazio extracellulare. Trasportano acidi nucleici e proteine, che riflettono lo stato e l’origine delle loro cellule madri. La loro capacità di attraversare le barriere biologiche e di circolare nei fluidi corporei le rende candidate ideali per la rilevazione non invasiva dei biomarcatori delle malattie. Con il supporto del programma di azioni Marie Skłodowska-Curie, il progetto NExGliO propone di sviluppare un test diagnostico che rilevi gli RNA non codificanti correlati al glioblastoma nelle vescicole extracellulari. Considerando che la diagnosi e il monitoraggio del glioblastoma si basano attualmente su biopsie invasive con accuratezza limitata, si prevede che l’approccio NExGliO contribuirà alla diagnosi precoce della malattia e migliorerà gli esiti clinici.

Obiettivo

Glioblastoma (GB) is the deadliest primary malignant brain tumour, with a median survival of less than one year while current diagnostic methods suffer from significant limitations, leading to misdiagnosis and poor progression monitoring and are accompanied by invasive biopsy. Currently, there are no blood-based biomarkers available as support tool for GB management. A promising approach for such systems are liquid biopsies based on Extracellular Vesicles (EVs) that present a promising and minimally invasive approach. EVs act as versatile communication hubs, transporting a meticulously selected cargos that include various RNA molecules. The specific composition of EVs is influenced by their cell of origin, highlighting their potential as specific biomarkers for aggressive tumours such as GB. The NExGliO project aims for the development of multiplex biosensors for simultaneous detection on array of EVs-based ncRNAs signature specialized for GB diagnosis. This will be achieved via noble metal NPs which are frequently utilized as SERS substrates due to their strong plasmonic properties for ncRNAs detection. Supporting AI technologies will be developed to improve early-stage cancer diagnosis through ncRNA signature identifying algorithms. The NExGliO Staff Exchange brings together internationally recognised experts with complementary expertise from molecular biology, chemistry, nanotechnology, and AI to develop a robust platform for the early diagnosis and monitoring of GB, thus reducing reliance on invasive procedures and improving survival rates. The secondments and local training will synergize expertise from both academic and non-academic partners for a robust collaboration and to generate knowledge transfer between the consortium partners.The direct application of this knowledge, will enhance the potential to introduce innovative products to the market and solidify their position in the relevant sector as well as benefit the careers of the involved personnel.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2024-SE-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Contributo netto dell'UE
€ 210 420,00
Indirizzo
6 CHRISTOU LADA STR
105 61 ATHINA
Grecia
Regione
Αττική Aττική Κεντρικός Τομέας Αθηνών
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partecipanti (8)

Partner (1)